|

HS-20117 Clinical Trials

1 actively recruiting trial

Also known as: PM1080

Pipeline

Phase 2/3: 1

Top Sponsors

  • Hansoh BioMedical R&D Company1

Indications

  • Non-Squamous Non-Small Cell Lung Cancer1
  • Lung Cancer1
  • Cancer1

Other1 trial

A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer
Phase 2/3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.